1. Susceptibility of Melanoma Cells to Targeted Therapy Correlates with Protection by Blood Neutrophils.
- Author
-
Wendlinger, Simone, Wohlfarth, Jonas, Siedel, Claudia, Kreft, Sophia, Kilian, Teresa, Junker, Sarah, Schmid, Luisa, Sinnberg, Tobias, Dischinger, Ulrich, Heppt, Markus V., Wistuba-Hamprecht, Kilian, Meier, Friedegund, Erpenbeck, Luise, Neubert, Elsa, Goebeler, Matthias, Gesierich, Anja, Schrama, David, Kosnopfel, Corinna, and Schilling, Bastian
- Subjects
MELANOMA prognosis ,THERAPEUTIC use of antineoplastic agents ,IN vitro studies ,MELANOMA ,SKIN tumors ,DRUG resistance in cancer cells ,RESEARCH funding ,NEUTROPHILS ,CELL physiology ,APOPTOSIS ,TREATMENT effectiveness ,CELLULAR signal transduction ,DESCRIPTIVE statistics ,LONGITUDINAL method ,CELL lines ,GENE expression ,CANCER patient psychology ,COMPARATIVE studies ,BIOMARKERS ,PHENOTYPES - Abstract
Simple Summary: Melanoma patients with high neutrophil counts often show impaired clinical response and poor prognosis, indicating that neutrophils can support melanoma progression. The precise mechanism responsible for this correlation, especially in the context of targeted therapy, still requires clarification. We show that peripheral blood neutrophils of patients with advanced melanoma are characterized by lower CD16 surface expression compared to healthy donors, which has been reported to be associated with tumor promotion. We provide evidence that melanoma cells under dual-targeted therapy can be protected in vitro by neutrophils from both patients and healthy donors. In addition, this protective effect is dependent on cell–cell contact, as well as on culture conditions, and is observed under nonadherence. Unraveling the mechanism, the interference with the protease activity of neutrophils reduced protection. Understanding the complex interaction of neutrophils and melanoma cells might aid in discovering methods to prevent the tumor-promoting effects by neutrophils in patients. Elevated levels of peripheral blood and tumor tissue neutrophils are associated with poorer clinical response and therapy resistance in melanoma. The underlying mechanism and the role of neutrophils in targeted therapy is still not fully understood. Serum samples of patients with advanced melanoma were collected and neutrophil-associated serum markers were measured and correlated with response to targeted therapy. Blood neutrophils from healthy donors and patients with advanced melanoma were isolated, and their phenotypes, as well as their in vitro functions, were compared. In vitro functional tests were conducted through nonadherent cocultures with melanoma cells. Protection of melanoma cell lines by neutrophils was assessed under MAPK inhibition. Blood neutrophils from advanced melanoma patients exhibited lower CD16 expression compared to healthy donors. In vitro, both healthy-donor- and patient-derived neutrophils prevented melanoma cell apoptosis upon dual MAPK inhibition. The effect depended on cell–cell contact and melanoma cell susceptibility to treatment. Interference with protease activity of neutrophils prevented melanoma cell protection during treatment in cocultures. The negative correlation between neutrophils and melanoma outcomes seems to be linked to a protumoral function of neutrophils. In vitro, neutrophils exert a direct protective effect on melanoma cells during dual MAPK inhibition. This study further hints at a crucial role of neutrophil-related protease activity in protection. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF